Tokyo - Delayed Quote JPY

Tokai Tokyo Financial Holdings, Inc. (8616.T)

484.00

+3.00

+(0.62%)

At close: 3:30:00 PM GMT+9

Stock futures, US-China tensions, May jobs report: 3 Things

US stock futures (ES=F, NQ=F, YM=F) dip in Monday's pre-market session after the S&P 500 (^GSPC) closed out its best May trading month since 1990. China has snapped back on President Trump's claims that the nation has violated its trade agreement with the US, now alleging the United States is in violation of its trade truce. The US Bureau of Labor Statistics (BLS) is due to release the May jobs report this Friday, June 6. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 7 minutes ago

STLD

NQ=F

YM=F
Is UnitedHealth Group (NYSE:UNH) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Simply Wall St. 16 minutes ago

UNH
BMO upgrades Nucor on compelling valuation, upside from tariff

Investing.com -- BMO Capital Markets upgraded Nucor Corp (NYSE:NUE) saying the stock currently trades at a "compelling" valuation, with long-term growth potential amid the recently announced U.S. steel tariffs.Nucor rating was bumped Outperform from Market Perform.

Investing.com 24 minutes ago

NUE
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). “The FDA approval of our third product, mNEXSPIKE...,” said Stéphane Bancel, Chief Executive Officer of Moderna. The FDA’s approval of mNEXSPIKE is based on results from a

Benzinga 40 minutes ago

MRNA
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints

Lyra Therapeutics (LYRA) said Monday that a phase 3 trial of LYR-210 bioabsorbable nasal implant met

PREMIUM
MT Newswires 52 minutes ago

LYRA
Are Hedge Funds Warming Up To Google Stock Amid Magnificent Seven Upheaval?

Here's what fundamental and technical analysis says about Google stock as generative AI presents new opportunities and risks for GOOGL stock.

Investor's Business Daily 55 minutes ago

NVDA

GOOG

AAPL
2 No-Brainer Growth Stocks to Buy in June

While the major indices have flatlined this year, several emerging tech stocks have posted jaw-dropping gains in 2025. Growth investors have had to dig deeper in 2025. With the S&P 500 flat year to date amid President Trump's global trade reset and persistent inflation, the broad-market rally has stalled.

Motley Fool 1 hour ago

IONQ-WS

PLTR
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells

Benzinga 1 hour ago

SNY

BPMC

NRIX
Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal

(Bloomberg) -- Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNYC Congestion Toll B

Bloomberg 1 hour ago

BNTX

PFE

SMMT
BioNTech soars 15% on cancer drug deal with Bristol Myers

Investing.com -- Shares in BioNTech (NASDAQ:BNTX) soared sharply Monday after Bristol-Myers Squibb Company (NYSE:BMY) agreed to pay $1.5 billion upfront to collaborate with the German biotech firm on the development of an experimental cancer treatment, the U.S. pharmaceutical company announced on Monday.

Investing.com 1 hour ago

BNTX

CELG-RT
Applied Digital Announces 250MW AI Data Center Lease With CoreWeave in North Dakota

DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD), a designer, builder and operator of next-generation digital infrastructure for HPC applications, has entered into two approximately 15-year lease agreements with CoreWeave, the AI Hyperscaler™. Under the lease agreements, Applied Digital will deliver 250 megawatts (MW) of critical IT load to host CoreWeave's artificial intelligence (AI) and high-performance computing (HPC) infrastructure at its Ellendale, North

GlobeNewswire 1 hour ago

APLD
Campbell Soup beats Q3 estimates, reaffirms guidance

Investing.com -- Campbell Soup Company reported better-than-expected third quarter results on Monday, as the food giant benefited from its recent Sovos Brands acquisition and saw improved consumption across income groups.

Investing.com 1 hour ago

CPB
DraftKings stock drops on new Illinois betting tax

Investing.com -- Shares of DraftKings (NASDAQ:DKNG) fell 5%, while Flutter saw a 3.3% decline following the announcement of new legislation in Illinois that introduces additional fees for online sportsbook operators. The market reacted negatively to the news that came as a surprise over the weekend, with Illinois passing its FY26 Budget, which incorporates an incremental fee structure targeting high-volume operators.

Investing.com 1 hour ago

DKNG
Market Chatter: Alphabet, Amazon-Backed Anthropic Hits $3 Billion Annualized Revenue as Demand for AI Services Surges

Alphabet (GOOGL) and Amazon (AMZN) backed Artificial intelligence developer Anthropic has reached $3

PREMIUM
MT Newswires 1 hour ago

AMZN

GOOG
Tesla Stock Is Falling. Is It a ‘Sell the News’ Month?

Tesla is set to launch its highly anticipated robotaxi service this month. Will that drive shares higher or will investors take profits now that the seminal event has arrived?

Barrons.com 1 hour ago

TSLA
Nebius Group announces private placement of $1 billion in aggregate principal amount of convertible notes

AMSTERDAM, June 02, 2025--Nebius Group N.V. ("Nebius Group" or the "Company"; NASDAQ: NBIS), a leading AI infrastructure company, today announced that it has entered into definitive agreements for a private placement of senior unsecured convertible notes in an aggregate principal amount of $1 billion, in two tranches: $500,000,000 aggregate principal amount of 2.00% convertible notes due 2029 (the "2029 Notes"), and $500,000,000 aggregate principal amount of 3.00% convertible notes due 2031 (the

Business Wire 1 hour ago

NBIS
5 Things to Know Before the Stock Market Opens

News of the day for June 2, 2025

Investopedia 1 hour ago

SNY

BPMC
Tesla's European sales rout continues but new Model Y boosts Norway deliveries

LONDON (Reuters) -Tesla's car sales fell sharply in several European markets including Sweden and Portugal in May, a fifth consecutive monthly decline that has been blamed on CEO Elon Musk's political activities and an outdated model lineup. However, Norway, where Tesla has started delivering revamped versions of its midsize SUV Model Y, provided a lone bright spot for the company as it prepares to roll out the refreshed vehicle in more European markets from this month.

Reuters 1 hour ago

TSLA
Trending tickers: Tesla, Palantir, Sanofi, Babcock and Indivior

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 1 hour ago

PLTR

TSLA

GBPEUR=X
BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration

Investing.com -- BioNTech SE (NASDAQ:BNTX) and Bristol Myers (NYSE:BMY) Squibb have announced their global collaboration for the co-development and co-commercialization of BioNTech’s experimental bispecific antibody BNT327, intended for use in various solid tumor types. The partnership aims to expedite and expand the development of this clinical candidate.

Investing.com 1 hour ago

BNTX

CELG-RT

Performance Overview

Return	8616.T	Nikkei 225 (^N225)
YTD	+0.83%	-6.08%
1-Year	-10.63%	-2.64%
3-Year	+49.71%	+36.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tokai Tokyo Financial Holdings, Inc. (8616.T)

Related News

Stock futures, US-China tensions, May jobs report: 3 Things

Is UnitedHealth Group (NYSE:UNH) A Risky Investment?

BMO upgrades Nucor on compelling valuation, upside from tariff

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints

Are Hedge Funds Warming Up To Google Stock Amid Magnificent Seven Upheaval?

2 No-Brainer Growth Stocks to Buy in June

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal

BioNTech soars 15% on cancer drug deal with Bristol Myers

Applied Digital Announces 250MW AI Data Center Lease With CoreWeave in North Dakota

Campbell Soup beats Q3 estimates, reaffirms guidance

DraftKings stock drops on new Illinois betting tax

Market Chatter: Alphabet, Amazon-Backed Anthropic Hits $3 Billion Annualized Revenue as Demand for AI Services Surges

Tesla Stock Is Falling. Is It a ‘Sell the News’ Month?

Nebius Group announces private placement of $1 billion in aggregate principal amount of convertible notes

5 Things to Know Before the Stock Market Opens

Tesla's European sales rout continues but new Model Y boosts Norway deliveries

Trending tickers: Tesla, Palantir, Sanofi, Babcock and Indivior

BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration

Performance Overview